Strategic and Operational Support to Maximize Investment Readiness & Post-Investment Value Creation

Alacrita supports biotech companies through both the fundraising process and the critical post-investment execution phase, delivering integrated strategic, technical, and operational expertise to maximize value at each milestone. Whether preparing for early institutional rounds, securing Series A/B growth capital, or executing against investor commitments, we act as a trusted advisor and hands-on extension of your leadership team.

Preparing for Investment: Strengthening Investor Readiness and Confidence


We support companies preparing for investment by strengthening their strategy, narrative, and investor readiness. This includes expert placement, development planning, investor materials, valuation modeling, and due diligence preparation, among other areas.

Our goal is to elevate investor readiness by aligning the company’s strategy, data, and narrative with the expectations of sophisticated investors.

.

  • Overall business and scientific strategy development
  • Development-stage gap analyses and risk mitigation planning
  • Integrated clinical, regulatory, CMC, and market strategy for lead and pipeline assets
  • Placement of interim executives (e.g. CEO, CSO, CMO, CTO) with proven biotech leadership experience
  • Functional specialists for program-specific needs (e.g. regulatory, clinical ops, CMC)
  • Refinement of investor-facing narrative and value proposition
  • Support for investor relations teams in preparing and managing investor-facing communications
  • Development of FAQs, messaging frameworks, and supporting materials for diligence and fundraising
  • Target product profile-based valuation models
  • Scenario modeling to support negotiations and term sheet evaluation
  • Independent assessments to validate investment case and future return potential
  • Investor deck development and scientific slide review
  • Full data room preparation including technical, regulatory, IP, and financial content
  • Optional support during investor meetings, diligence calls, and term sheet discussions


Post-Investment Execution: Delivering on the Investment Thesis

We help portfolio companies translate strategy into execution by providing expert leadership, development planning, and functional support across clinical, regulatory, CMC, and valuation.

After capital is secured, we support biotech teams in accelerating execution with focus and precision, helping them advance toward key milestones and value inflection points efficiently.

  • Strategic guidance to ensure development activities remain aligned with scientific objectives and business strategy
  • Input on program prioritization based on scientific, regulatory, and commercial considerations
  • Rapid deployment of interim leadership for mission-critical functions
  • Functional expertise and support across regulatory, clinical, and CMC to enable focused and efficient execution
  • Development of valuation models based on product profiles and commercial potential
  • Scenario planning to guide decision-making, fundraising strategy, and milestone communications
  • Identification and evaluation of complementary assets to expand the pipeline or support platform strategy
  • Strategic assessment of scientific rationale, IP status, and commercial potential
  • Competitive landscape analysis to support asset evaluation, differentiation, and portfolio planning
  • Development of investor updates, board materials, and milestone reporting packages